Dr. Li Malmberg is a veteran CMC executive with nearly 30 years of experience in product development and manufacturing, shaping both technical and strategic decisions across CMC functions and external collaborations. She now works as an independent consultant after a long career in the pharmaceutical and biotech industries. Most recently, she held senior leadership roles as Chief Technology Officer and Senior Vice President at Magenta Therapeutics and Xilio Therapeutics, where she built CMC and technical operations teams and guided product development strategy.
Between 2017 and 2020, Li served as Vice President of Biologics Development and Manufacturing at Celgene, overseeing global technical development and manufacturing for all biologics programs. She built an organization of more than 150 scientists and engineers with an annual budget over $100 million and led CMC development for 15 biologics programs, culminating in the approval of REBLOZYL, Celgene’s first biologic therapy.
Earlier, she was Director and Head of Process Sciences at AbbVie, leading a team responsible for biologics development from clinical to commercial stages, including Humira. Prior to that, she held a series of R&D leadership roles at AbbVie and Abbott, supporting small-molecule CMC development and discovery.
